Acerta Pharma B.V.
21Patents
21Active
21Granted
51Portfolio score
Filing activity: Apr 11, 2013 → Aug 16, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10272083B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 8 | Active |
| US9796721B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Chemistry; Metallurgy | 5 | Active |
| US9949971B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor | Chemistry; Metallurgy | 3 | Active |
| US11771696B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 3 | Active |
| US10328080B2 | Therapeutic combination of PI3K inhibitor and a BTK inhibitor | Human Necessities | 2 | Active |
| US9522917B2 | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization | Chemistry; Metallurgy | 2 | Active |
| US11090302B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 2 | Active |
| US11654143B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | Human Necessities | 2 | Active |
| US11166951B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | Human Necessities | 1 | Active |
| US11110088B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Chemistry; Metallurgy | 1 | Active |
| US10736893B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Chemistry; Metallurgy | 1 | Active |
| US10167291B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Chemistry; Metallurgy | 0 | Active |
| US12263164B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Chemistry; Metallurgy | 0 | Active |
| US10640509B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma | Chemistry; Metallurgy | 0 | Active |
| US12024520B2 | Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide | Chemistry; Metallurgy | 0 | Active |
| US10858364B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Human Necessities | 0 | Active |
| US9937171B2 | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase | Human Necessities | 0 | Active |
| US11820777B2 | Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | Chemistry; Metallurgy | 0 | Active |
| US11154554B2 | Therapeutic combinations of a MEK inhibitor and a BTK inhibitor | Human Necessities | 0 | Active |
| US11590167B2 | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US11059829B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.